Management of hyperkalemia in dialysis patients

被引：82

作者：

Putcha, Nirupama ^{[1
]}

Allon, Michael ^{[1
]}

机构：

[1] Div Nephrol, Birmingham, AL 35294 USA

来源：

SEMINARS IN DIALYSIS | 2007年 / 20卷 / 05期

关键词：

D O I：

10.1111/j.1525-139X.2007.00312.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Hyperkalemia is common in patients with end-stage renal disease, and may result in serious electrocardiographic abnormalities. Dialysis is the definitive treatment of hyperkalemia in these patients. Intravenous calcium is used to stabilize the myocardium. Intravenous insulin and nebulized albuterol lower serum potassium acutely, by shifting it into the cells. Despite their widespread use, neither intravenous bicarbonate nor cation exchange resins are effective in lowering serum potassium acutely. Prevention of hyperkalemia currently rests largely upon dietary compliance and avoidance of medications that may promote hyperkalemia. Prolonged fasting may provoke hyperkalemia, which can be prevented by administration of intravenous dextrose.

引用

页码：431 / 439

页数：9

共 73 条

[41]

JAMISON RL, 2001, NEPHROLOGY ROUNDS, V4, P1

[42]

Johnson K, 1976, Clin Nephrol, V5, P266

[43] A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients [J].